Merck & Co (MRK) Earnings Date & Reports

Key Takeaways

• Revenue exceeded expectations: Merck posted second-quarter 2026 sales of $16.6 billion, up 5% year over year and ahead of the $16.41 billion consensus estimate.
• Non-GAAP EPS beat convincingly: The company reported an adjusted loss of $0.13 per share, significantly better than the $0.27 loss Wall Street had forecast.
• Terns acquisition drove the bottom-line loss: Both GAAP and non-GAAP results included a $2.31 per share charge tied to the $6.8 billion acquisition of Terns Pharmaceuticals.
• New product launches gained momentum: Recently launched drugs generated $1.5 billion in quarterly revenue, more than double the $0.6 billion from the same period last year.
• Full-year revenue guidance was raised: Merck lifted and narrowed its 2026 sales outlook to $66.3 billion–$67.3 billion, while lowering EPS guidance to reflect acquisition-related costs.

Earnings Context and Why It Matters

Merck's second-quarter 2026 results, released on August 4, arrived at a pivotal moment for the pharmaceutical giant. With its flagship cancer immunotherapy KEYTRUDA facing eventual patent expiration later this decade, the company has embarked on an ambitious portfolio transformation strategy aimed at building a diversified pipeline of growth drivers. This quarter offered investors a concrete look at how that strategy is translating into commercial reality. The results also captured the financial impact of Merck's aggressive business development activity — most notably the $6.8 billion Terns Pharmaceuticals acquisition — making the quarter an important barometer of whether near-term deal costs are being offset by underlying operational strength and pipeline progress.

Reported Results

Merck reported worldwide sales of $16.6 billion for the second quarter of 2026, a 5% increase from $15.8 billion in the prior-year period, or 4% excluding the impact of foreign exchange. The top-line figure comfortably exceeded the analyst consensus of $16.41 billion.

On the bottom line, Merck recorded a non-GAAP (Generally Accepted Accounting Principles) loss of $0.13 per share. While a loss on its face, this result substantially outperformed the consensus estimate of a $0.27 loss per share. The GAAP loss was $0.54 per share, compared with a profit of $1.76 per share in the second quarter of 2025. Both GAAP and non-GAAP figures were weighed down by a $2.31 per share charge related to the Terns Pharmaceuticals acquisition.

The KEYTRUDA family — including KEYTRUDA QLEX, a subcutaneous formulation — generated $8.4 billion in sales, up 4% on a constant-currency basis. WINREVAIR, Merck's treatment for pulmonary arterial hypertension (high blood pressure in the lungs), continued its rapid uptake with sales rising 75% to $588 million. WELIREG, used in certain kidney cancer patients, climbed 67% to $271 million. GARDASIL vaccine sales reached $1.17 billion, up 4%. Animal Health contributed $1.78 billion, an 8% increase.

Notably, revenue from recently launched products — including WINREVAIR, KEYTRUDA QLEX, CAPVAXIVE, OHTUVAYRE, ENFLONSIA, and others — totaled $1.5 billion, more than doubling from $0.6 billion a year earlier. Non-GAAP gross margin came in at 81.1%, down 1.1 percentage points, primarily due to higher inventory reserves.

AI Screener

For investors looking to identify pharmaceutical stocks with similar earnings momentum or breakout technical patterns, Tickeron's AI Screener offers a powerful solution. This AI-driven stock and ETF discovery tool enables traders and investors to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and proprietary AI-generated signals. Whether scanning for biotech breakout candidates, undervalued healthcare names, or stocks exhibiting specific chart formations ahead of their earnings reports, the AI Screener helps surface relevant trade ideas more efficiently than manual screening methods. Explore the platform to see how data-driven filtering can complement your earnings research.

Market Reaction and Investor Sentiment

Merck shares rose approximately 1.4% in pre-market trading following the earnings release on August 4, reflecting investor approval of the revenue beat and the strong performance from the company's newer product lineup. The stock, which closed the prior session at $127.77, traded near the upper end of its 52-week range of $77.58 to $135.05, underscoring the market's broader confidence in Merck's diversification strategy.

That said, the post-earnings move was relatively measured. The reduction in full-year EPS guidance — from $5.04–$5.16 to $2.66–$2.76 — was expected and well-telegraphed, as it primarily reflects the previously announced Terns acquisition charge rather than operational weakness. Investors appeared to look through the one-time accounting impact and focus instead on the underlying sales trajectory, pipeline milestones, and the raised revenue forecast.

Forward Outlook and Key Factors to Monitor

Looking ahead, Merck's investment narrative will continue to revolve around its ability to sustain growth momentum beyond KEYTRUDA. The company now guides for full-year 2026 revenue of $66.3 billion to $67.3 billion, implying 2% to 4% growth, and non-GAAP EPS of $2.66 to $2.76 — a range that incorporates roughly $2.43 per share in total charges tied to the Terns deal.

Several catalysts stand out on the horizon. The July FDA (U.S. Food and Drug Administration) approval of LIPFENDRA (enlicitide), the first once-daily oral PCSK9 inhibitor (a class of cholesterol-lowering drugs) for adults with hypercholesterolemia, opens a large and largely injectable-dominated cardiometabolic market. Meanwhile, the Phase 3 readout for sac-TMT — an investigational antibody-drug conjugate — in advanced endometrial cancer met both overall survival and progression-free survival endpoints, marking the first positive pivotal data from Merck's broad sac-TMT clinical program, which spans 17 ongoing Phase 3 trials.

In HIV, the presentation of positive Phase 3 results for the once-weekly oral regimen combining islatravir and lenacapavir (ISL/LEN), developed in collaboration with Gilead, positions Merck to potentially capture a share of a significant treatment market. On the immunology front, tulisokibart met primary and key secondary endpoints in a Phase 3 ulcerative colitis induction study, though a separate trial in systemic sclerosis-associated interstitial lung disease was discontinued after missing its primary endpoint — a reminder of the inherent risk in drug development.

Cost management will also remain in focus. Operating expenses are now expected to reach $42.0 billion to $42.7 billion for the full year, reflecting not only acquisition accounting but also continued investment in launches and clinical programs. With gross margin projected around 81%, any supply chain or manufacturing headwinds could draw scrutiny. Investors should monitor the pace of new product adoption, particularly LIPFENDRA's early commercial trajectory, alongside further sac-TMT data readouts and the evolving competitive landscape in oncology and vaccines.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations